Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Accured Expenses (2019 - 2025)

BridgeBio Pharma's Change in Accured Expenses history spans 7 years, with the latest figure at $68.7 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 929.49% year-over-year to $68.7 million; the TTM value through Sep 2025 reached $64.4 million, up 292.02%, while the annual FY2024 figure was $17.0 million, 117.71% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $68.7 million at BridgeBio Pharma, up from $3.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $68.7 million in Q3 2025 and bottomed at -$19.4 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $6.7 million (2024), against an average of $4.1 million.
  • The largest annual shift saw Change in Accured Expenses plummeted 23700.0% in 2021 before it soared 929.49% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $11.8 million in 2021, then crashed by 175.88% to -$9.0 million in 2022, then surged by 221.04% to $10.9 million in 2023, then increased by 5.06% to $11.4 million in 2024, then surged by 502.03% to $68.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Change in Accured Expenses are $68.7 million (Q3 2025), $3.7 million (Q2 2025), and -$19.4 million (Q1 2025).